For almost four decades, my work has focused on one challenge: improving the delivery and
efficacy of anticancer therapeutics. Working on the hypothesis that the abnormal tumor …

Bevacizumab is the first antiangiogenic therapy proven to slow metastatic disease
progression in patients with cancer. Although it has changed clinical practice, some patients …

Antiangiogenic therapy has shown clear activity and improved survival benefit for certain
tumor types. However, an incomplete understanding of the mechanisms of action of …

Angiogenesis is a key component of cancer growth, invasion and metastasis. Therefore,
inhibition of angiogenesis is an attractive strategy for the treatment of cancer. We …

Purpose: We conducted a single-arm phase II study of cediranib, a pan-VEGFR tyrosine
kinase inhibitor, in patients with advanced hepatocellular carcinoma (HCC). Experimental …

Antiangiogenic therapy for cancer has gone from an intriguing hypothesis in the 1970s to an
accepted treatment approach for many cancer types. It has also become a standard of care …

JNCI| Editorials 763 jnci. oxfordjournals. org intense efforts to develop therapies that target
the VEGF pathway. Currently, there are nine antiangiogenic drugs approved by the US Food …

The success of sorafenib in prolonging survival of patients with hepatocellular carcinoma
(HCC) makes therapeutic inhibition of angiogenesis a component of treatment for HCC. To …

The hunt for biomarkers for anti-VEGF agent bevacizumab is ongoing since last decade with
no success. Identifying robust biomarkers for stratifying patients and for monitoring response …

Over the last decade, anti-angiogenic therapy for cancer has become increasingly used as a
standard therapeutic approach for many cancer types. It has also become a standard of care …